JP2024505018A5 - - Google Patents
Info
- Publication number
- JP2024505018A5 JP2024505018A5 JP2023544779A JP2023544779A JP2024505018A5 JP 2024505018 A5 JP2024505018 A5 JP 2024505018A5 JP 2023544779 A JP2023544779 A JP 2023544779A JP 2023544779 A JP2023544779 A JP 2023544779A JP 2024505018 A5 JP2024505018 A5 JP 2024505018A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21153332 | 2021-01-25 | ||
| EP21153332.8 | 2021-01-25 | ||
| PCT/EP2022/051619 WO2022157385A1 (en) | 2021-01-25 | 2022-01-25 | Naltrexone compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024505018A JP2024505018A (ja) | 2024-02-02 |
| JP2024505018A5 true JP2024505018A5 (https=) | 2025-01-20 |
| JPWO2022157385A5 JPWO2022157385A5 (https=) | 2025-01-20 |
Family
ID=74236099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023544779A Pending JP2024505018A (ja) | 2021-01-25 | 2022-01-25 | ナルトレキソン組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240108583A1 (https=) |
| EP (1) | EP4281046B1 (https=) |
| JP (1) | JP2024505018A (https=) |
| KR (1) | KR20230136180A (https=) |
| CN (1) | CN117545472A (https=) |
| AU (1) | AU2022211609A1 (https=) |
| CA (1) | CA3207647A1 (https=) |
| IL (1) | IL304652A (https=) |
| WO (1) | WO2022157385A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022103638A1 (en) * | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Cannabinoids in the treatment of autism spectrum disorder |
| GB202109018D0 (en) * | 2021-06-23 | 2021-08-04 | Ldn Pharma Ltd | Treatment with an agonist of a 5-hydroxytryptamine (5-ht) receptor |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030035839A1 (en) * | 2001-05-15 | 2003-02-20 | Peirce Management, Llc | Pharmaceutical composition for both intraoral and oral administration |
| GB0513984D0 (en) * | 2005-07-07 | 2005-08-17 | Teva Pharma | Dosage form |
| EP1980245A1 (en) * | 2007-04-11 | 2008-10-15 | Cephalon France | Bilayer lyophilized pharmaceutical compositions and methods of making and using same |
| GB2478595B (en) * | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
| US9205081B2 (en) * | 2010-04-29 | 2015-12-08 | Allodynic Therapeutics, Llc | Combinations of opiod/TLR4 antagonist and a cyclooxygenase (COX) inhibitor for use in the treatment of pain |
| US20140371210A1 (en) * | 2011-10-13 | 2014-12-18 | Jaleva Pharmaceuticals, Llc | Methods and compositions for rapid transbuccal delivery of active agents |
| GB201308440D0 (en) * | 2013-05-10 | 2013-06-19 | Dalgleish Angus | Therapeutic |
| BR112017018316A2 (pt) * | 2015-02-27 | 2018-04-17 | Ebbu Llc | composições compreendendo combinações de canabinoides purificados, com pelo menos um flavonoide, terpeno ou mineral |
| EP3939570A1 (en) * | 2016-02-18 | 2022-01-19 | Immune Therapeutics, Inc. | Naltrexone for treating or preventing autoimmune and inflammatory diseases |
| JP6968184B2 (ja) * | 2016-10-25 | 2021-11-17 | キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド | 速崩壊多層錠のための異なる密度の組成物 |
| US10517834B2 (en) * | 2017-05-16 | 2019-12-31 | Owen Murray | Fast dissolving tablet formulations and methods of making thereof |
| EP3482751A1 (en) * | 2017-11-14 | 2019-05-15 | LDN Pharma Limited | Cancer treatment |
| GB201805207D0 (en) * | 2018-03-29 | 2018-05-16 | Ldn Pharma Ltd | Autoimmune therapy |
| CN109316454B (zh) * | 2018-11-26 | 2021-06-15 | 正大制药（青岛）有限公司 | 一种骨化三醇制剂 |
| EP3934647A1 (en) * | 2019-03-06 | 2022-01-12 | LDN Pharma Limited | Method for determining efficacy |
| GB201903546D0 (en) * | 2019-03-15 | 2019-05-01 | Ldn Pharma Ltd | Cancer treatment |
| US12453750B2 (en) * | 2019-03-21 | 2025-10-28 | Alvit Lcs Pharma Ltd. | Fixed dose combination of cannabinoids and medical mushrooms for prevention and treatment of cancer, inflammatory or immune-mediated inflammatory diseases |
-
2022
- 2022-01-25 JP JP2023544779A patent/JP2024505018A/ja active Pending
- 2022-01-25 CN CN202280011349.8A patent/CN117545472A/zh active Pending
- 2022-01-25 KR KR1020237028839A patent/KR20230136180A/ko active Pending
- 2022-01-25 WO PCT/EP2022/051619 patent/WO2022157385A1/en not_active Ceased
- 2022-01-25 US US18/273,710 patent/US20240108583A1/en active Pending
- 2022-01-25 EP EP22702657.2A patent/EP4281046B1/en active Active
- 2022-01-25 CA CA3207647A patent/CA3207647A1/en active Pending
- 2022-01-25 AU AU2022211609A patent/AU2022211609A1/en active Pending
-
2023
- 2023-07-23 IL IL304652A patent/IL304652A/en unknown